spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  neuroendocrine tumors 

 HSMN NewsFeed - 25 Oct 2022
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-B
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jun 2022
Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 12 Jan 2022
DALI Medical's SAN(R)Light Passive Safety Needle coupled with a novel Drug Product, Enabling User-friendly Administration
Devices Drug Delivery Product Launch
 HSMN NewsFeed - 1 Dec 2021
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Nov 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement for Octreotide Long Acting Injectable (LAI) Microsphere for Neuroendocrine Cancers and Acromegaly
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 30 Jan 2018
FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals' DP1038 for the Treatment of Acromegaly
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Dec 2017
Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jun 2017
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 May 2017
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jan 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 8 Dec 2016
Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT(R)
Biopharmaceuticals Radiology Oncology Reimbursement
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2016
Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera(R)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jul 2016
David Meek appointed as Chief Executive Officer of Ipsen
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2015
Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing
Biopharmaceuticals Acquisitions Licensing Venture Capital
 HSMN NewsFeed - 20 Mar 2015
OXiGENE, Inc. Announces $10 Million At-the-Market Registered Direct Offering
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 Feb 2015
Chiasma Announces Completion of $70 Million Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Jul 2014
Ipsen submits marketing authorization applications in the US and Europe for Somatuline(R) (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jan 2014
Ipsen to set up its own US oncology team for Somatuline(R) Depot(R) (lanreotide) Injection in neuroendocrine tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Feb 2013
Roche and Chiasma Announce Collaboration to Develop and Commercialize Chiasma's Octreolin(R) for Acromegaly and Neuroendocrine Tumors
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2011
Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Oct 2010
Phase III Novartis Data Show Potential Benefit of Afinitor(R) Plus Sandostatin(R) LAR Depot in Patients with Advanced Carcinoid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2010
Novartis Drug SOM230 is First Medical Therapy to Show Efficacy in a Phase III Trial in Cushing's Disease, a Debilitating Hormonal Disorder
Biopharmaceuticals
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2010
Pivotal Phase III Trial of Novartis Drug Afinitor(R) Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2010
Neotropix Announces Enrollment of Patients in NCI-Sponsored Phase II Clinical Trial for Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2010
Data Show Progression-Free Survival Advantage with Sutent(R) in Patients with Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2009
Delcath Systems Reports Substantial Progress
Devices Oncology
 HSMN NewsFeed - 25 Jun 2009
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2009
Delcath Systems Granted Third Orphan Drug Designation
Biopharmaceuticals Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 14 May 2009
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval to Proceed With Phase 3 Development of Onalta(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Mar 2009
GE Healthcare Announces Data from Phase III Study of AdreView in Heart Failure Patients
Biopharmaceuticals Cardiology Radiology
 HSMN NewsFeed - 12 Mar 2009
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Mar 2009
Molecular Insight Receives Special Protocol Assessment Approval From FDA for Phase 2 Trial of Azedra(TM), a Radiotherapeutic to Treat Neuroendocrine Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Sep 2008
FDA Approves GE Healthcare's AdreView (Iobenguane I 123 Injection) Diagnostic Agent for Detecting Neuroendocrine Tumors in Children, Adults
Biopharmaceuticals Radiology FDA
 HSMN NewsFeed - 16 Jun 2008
Tercica Announces Results from Increlex(R) IGFD Patient Registry and Other Increlex(R) Studies at the 90th Meeting of the Endocrine Society
Biopharmaceuticals
 HSMN NewsFeed - 3 Jun 2008
Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2008
Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Devices Drug Delivery Oncology
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2008
Delcath and Aethlon Medical Sign Collaboration Agreement to Research and Develop Advanced Filtration Technology
Devices Oncology
 HSMN NewsFeed - 3 Jan 2008
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 20 Nov 2007
Delcath Resumes Enrollment in Phase III and Phase II Trials
Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 15 Oct 2007
Covidien and BioSynthema Sign Exclusive Agreements for Cancer Therapy Technology
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 4 Oct 2007
Delcath Systems Issues CEO Letter to Shareholders
Devices Drug Delivery Oncology
 HSMN NewsFeed - 30 Aug 2007
Somatuline(R) Depot Receives FDA Marketing Approval for the Treatment of Acromegaly
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 May 2007
Molecular Insight Pharmaceuticals, Inc. Initiates Azedra(TM) Therapeutic Trial in Neuroendocrine Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2007
Molecular Insight Pharmaceuticals, Inc. Announces Appointment of Norman LaFrance, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2007
Molecular Insight Pharmaceuticals, Inc. Acquires Clinical Stage, Targeted Radiotherapeutic Candidate Onalta(TM) (Formerly OctreoTher(TM))
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 16 Jan 2007
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Accepted for Filing by FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jan 2007
FDA Accepts for Filing a New Drug Application (NDA) for Somatuline(R) Autogel(R)
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2006
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Nov 2006
Tercica Reports Somatuline(R) Autogel(R) NDA for Acromegaly Submitted to FDA
Biopharmaceuticals
 HSMN NewsFeed - 11 Jul 2006
RITA Announces Launch of LC Bead(TM) Embolization Product in U.S.
Devices Oncology
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
neuroendocrine tumors
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.